catechin has been researched along with Peripheral Nerve Injuries in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benov, L; Khan, KM; Renno, WM | 2 |
| Al-Maghrebi, M; Khraishah, H; Rao, MS; Renno, WM | 1 |
| Alberch, J; Boadas-Vaello, P; Puig, T; Turrado, C; Verdú, E; Vidal-Sancho, L; Xifró, X | 1 |
| Akdag, R; Alagoz, F; Belen, AD; Cetinalp, NE; Dalgic, A; Divanlioglu, D; Guvenc, Y; Helvacioglu, F; Koksal, I; Take, G; Yildirim, AE | 1 |
| Huang, CC; Shieh, JY; Tsai, MH; Tseng, CY; Tu, HC; Wei, IH | 1 |
6 other study(ies) available for catechin and Peripheral Nerve Injuries
| Article | Year |
|---|---|
Possible role of antioxidative capacity of (-)-epigallocatechin-3-gallate treatment in morphological and neurobehavioral recovery after sciatic nerve crush injury.
Topics: Animals; Antioxidants; Axons; Catechin; Crush Injuries; Disease Models, Animal; Hyperalgesia; Male; Motor Activity; Nerve Regeneration; Neuroprotective Agents; Oxidative Stress; Peripheral Nerve Injuries; Random Allocation; Rats, Wistar; Recovery of Function; RNA, Messenger; Sciatic Nerve; Sciatic Neuropathy; Spinal Cord | 2017 |
(-)-Epigallocatechin-3-gallate modulates spinal cord neuronal degeneration by enhancing growth-associated protein 43, B-cell lymphoma 2, and decreasing B-cell lymphoma 2-associated x protein expression after sciatic nerve crush injury.
Topics: Animals; bcl-X Protein; Catechin; Disease Models, Animal; GAP-43 Protein; Immunohistochemistry; Male; Nerve Crush; Nerve Degeneration; Neuroprotective Agents; Peripheral Nerve Injuries; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; Recovery of Function; Reverse Transcriptase Polymerase Chain Reaction; Sciatic Nerve; Spinal Cord | 2015 |
Novel epigallocatechin-3-gallate (EGCG) derivative as a new therapeutic strategy for reducing neuropathic pain after chronic constriction nerve injury in mice.
Topics: Animals; Catechin; Cell Membrane; Cytokines; Fatty Acid Synthase, Type I; Fatty Acids; Gene Expression Regulation; Hyperalgesia; Male; Mice; Neuralgia; Pain; Pain Threshold; Peripheral Nerve Injuries; Spinal Cord Injuries | 2015 |
Biochemical and histopathological effects of catechin on experimental peripheral nerve injuries.
Topics: Animals; Catechin; Disease Models, Animal; Male; Neuroprotective Agents; Peripheral Nerve Injuries; Rats; Rats, Wistar | 2015 |
Is there a role for neurotrophic factors and their receptors in augmenting the neuroprotective effect of (-)-epigallocatechin-3-gallate treatment of sciatic nerve crush injury?
Topics: Animals; Brain-Derived Neurotrophic Factor; Catechin; Drug Interactions; Glial Cell Line-Derived Neurotrophic Factor; Male; Nerve Regeneration; Neurons; Neuroprotective Agents; Neurotrophin 3; Peripheral Nerve Injuries; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Nerve Growth Factor; Sciatic Nerve | 2016 |
(-)-Epigallocatechin gallate attenuates NADPH-d/nNOS expression in motor neurons of rats following peripheral nerve injury.
Topics: Animals; Brain Stem; Catechin; Cell Death; Dose-Response Relationship, Drug; Male; Motor Neurons; NADP; Nerve Crush; Neuroprotective Agents; Nitric Oxide Synthase Type I; Peripheral Nerve Injuries; Rats; Rats, Wistar | 2011 |